Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial

Tolaney, SM; Tarantino, P; Graham, N; Tayob, N; Parè, L; Villacampa, G; Dang, C; Yardley, DA; Moy, B; Marcom, PK; Albain, KS; Rugo, HS; Ellis, MJ; Shapira, I; Wolff, AC; Carey, LA; Barroso-Sousa, R; Villagrasa, P; DeMeo, M; DiLullo, M; Zanudo, JGT; Weiss, J; Wagle, N; Partridge, AH; Waks, AG; Hudis, CA; Krop, IE; Burstein, HJ; Prat, A; Winer, EP

Tolaney, SM (通讯作者)，Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.

LANCET ONCOLOGY, 2023; 24 (3): 273

Abstract

Background We aimed to report on long-term outcomes of patients with small, node-negative, HER2-positive breast cancer treated with adjuvant paclitaxe......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索